Arfolitixorin

DRUG4 trials

Sponsors

Isofol Medical AB (publ), Isofol Medical AB, Vastra Gotaland Region

Conditions

Colo-rectal CancerMetastatic Colorectal CancerMetastatic Colorectal Cancer (mCRC)metastatic colorectal cancer

Phase 1

Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate

Vastra Gotaland RegionMetastatic Colorectal Cancer

Start: 2020-02-05End: 2021-11-30Target: 30Updated: 2020-08-27

A Phase 1b/2 study of arfolitixorin combined with 5-fluorouracil, oxaliplatin, and bevacizumab in first-line treatment of metastatic colorectal cancer

RecruitingCTIS2024-516802-43-00

Isofol Medical AB (publ)metastatic colorectal cancer

Start: 2025-04-09Target: 60Updated: 2025-10-23

A Clinical Study of Arfolitixorin in Patients With mCRC

RecruitingNCT06922383

Isofol Medical ABMetastatic Colorectal Cancer (mCRC)

Start: 2025-04-10End: 2029-12-31Target: 90Updated: 2026-06-29

Phase 3

A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer

CompletedNCT03750786

Isofol Medical ABColo-rectal Cancer

Start: 2018-12-18End: 2022-11-18Updated: 2023-10-26

Related Papers

Abstract CT218: Phase 1b/2 study of arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab as first-line therapy for metastatic colorectal cancer (mCRC)

Cancer Research2026-04-17

Phase 1b/2 study of arfolitixorin in combination with 5-fluorouracil (5FU), oxaliplatin, and bevacizumab as first-line therapy for metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2026-01-10

The importance of treatment handling and compliance on overall response rate in a phase III study of metastatic colorectal cancer: Post-hoc per protocol analyses of the AGENT trial.

Journal of Clinical Oncology2025-01-27

A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial

Cancer Research Communications2023-12-077 citations

A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.

2022-09-291 citations

AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer.

Journal of Clinical Oncology2020-02-011 citations

Increasing Effectiveness of Chemo for Metastatic Colorectal Cancer

Oncology Times2019-04-11